moderate

Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints

SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

2 weeks ago

Vagaro Research Shows 90% of Service Professionals Face High Stress & Burnout

SAN FRANCISCO--(BUSINESS WIRE)--New data from the 2025 Vagaro Vantage Report reveals higher levels of stress and other mental health concerns…

2 months ago